Lack of dynamics in the MabA active site kills the enzyme activity: practical consequences for drug-design studies

G. Poncet-Montange, Stéphanie Ducasse-Cabanot, Gilles Labesse, Martin Cohen‐Gonsaud

Acta Crystallographica Section D Biological Crystallography · 2007 · 14 citations · 9 references

Concepts

Abstract

The MabA protein from Mycobacterium tuberculosis is a validated drug target. Previous structural studies of this protein showed dynamic behaviour in the catalytic site and described motion between an open 'active' holo form (with NADP) and a closed 'inactive' apo form (without NADP). Here, a mutation (G139A) is reported that leads to complete protein inactivation and freezes the catalytic site into its closed form, even in the presence of the cofactor. This observation suggests a new way to develop anti-MabA drugs via protein stabilization of the 'inactive' form.

References

9